


I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
on April 17, 2006

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
Examining Group 1632
Patent Application
Docket No. USF-182XC1
Serial No. 10/655,873

Glenn P. Ladwig
Glenn P. Ladwig, Patent Attorney



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Louis D. Lieto, Ph.D.
Art Unit : 1632
Applicants : Shyam S. Mohapatra, Mukesh Kumar
Serial No. : 10/655,873
Filed : September 5, 2003
For : Genetic Adjuvants for Immunotherapy

MS RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.

The applicants respectfully assert that the substantive provisions of 37 C.F.R. §§1.97 and 1.98 are met by the foregoing statement.


Respectfully submitted,

Glenn P. Ladwig

Glenn P. Ladwig
Patent Attorney
Registration No. 46,853
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: P.O. Box 142950
Gainesville, FL 32614-2950

GPL/mv

Attachments: Form PTO/SB/08 (1 page); copies of references cited therein



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	1	of	1	Application Number	10/655,873
				Filing Date	September 5, 2003
				First Named Inventor	Shyam S. Mohapatra
				Group Art Unit	1632
				Examiner Name	Louis D. Lieto
				Attorney Docket Number	USF-182XC1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	R1	FLOTTE, T.R. and LAUBE, B.L. "Gene therapy in cystic fibrosis" <i>CHEST</i> , 2001, 120:124S-131S.		
	R2	GRAY, P.W. and GOEDDEL, D.V. "Cloning and expression of murine immune interferon cDNA" <i>Proc. Natl. Acad. Sci. USA</i> , 1983, 80:5842-5846.		
	R3	JOOSS, K. and CHIRMULE, N. "Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy" <i>Gene Therapy</i> , 2003, 10:955-963.		
	R4	KAY, M.A. et al. "Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics" <i>Nature Med.</i> , 2001, 7:33-40.		
	R5	MOHAPATRA, S.M. et al., poster materials presented at the American Academy of Allergy Asthma in March 2002 and presented at the Immunology and American Thoracic Society in May 2002.		
	R6	PAYNE, L.G. et al. "Particle-mediated DNA vaccination of mice, monkeys and men: Looking beyond the dogma" <i>Curr Opin Mol Therap</i> , 2002, 4:459-466.		
	R7	SOMIA, N. and VERMA, I.M. "Gene therapy: Trials and tribulations" <i>Nature Rev.</i> , 2000, 1:91-99.		
	R8	XIU, Q. et al. "Effect of intratracheally administered IL-12 recombinant adenovirus on ovalbumin induced bronchial hyresponsiveness in mouse model" <i>Chin J Tuberc Respir Dis</i> , 2001, 24:298-301.		
	R			
	R			
	R			
	R			
	R			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.